2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Mario Dicato, MD, Hematology-Oncology Service, Centre Hospitalier de Luxembourg, discusses 3 agents used for the treatment or reduction of thrombocytopenia for patients with cancer.
Mario Dicato, MD, Hematology-Oncology Service, Centre Hospitalier de Luxembourg, discusses 3 agents used for the treatment or reduction of thrombocytopenia for patients with cancer.
Rivaroxaban (Xarelto), apixaban (Eliquis), and edoxaban (Savaysa) are currently available for patients, Dicato explains. However, these agents have been criticized due to a lack of data demonstrating efficacy and safety.
An advantage is that patients do not need to undergo platelet testing after receiving these oral treatments, he adds.
Related Content: